DFCM
ARQT icon

Dark Forest Capital Management’s Arcutis Biotherapeutics ARQT Stock Holding History

Dark Forest Capital Management’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-45,758
Closed -$1.33M – 796
2025
Q4 		$1.33M Buy
45,758
+18,391
+67% +$471K 0.06% 555
2025
Q3 		$516K Buy
+27,367
New +$432K 0.02% 919
2024
Q4 		– Sell
-16,817
Closed -$156K – 929
2024
Q3 		$156K Sell
16,817
-10,795
-39% -$107K 0.02% 899
2024
Q2 		$257K Buy
27,612
+6,362
+30% +$57.5K 0.05% 491
2024
Q1 		$211K Buy
+21,250
New +$159K 0.04% 604
2023
Q4 		– Sell
-74,293
Closed -$394K – 494
2023
Q3 		$394K Buy
+74,293
New +$632K 0.03% 803

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Dark Forest Capital Management's ARQT Position: Q1 2026 in Review

Dark Forest Capital Management sold out of Arcutis Biotherapeutics (ARQT) in Q1 2026, closing a stake of 45,758 shares — an estimated $1.33M sold.

Dark Forest Capital Management first reported a position in ARQT in Q3 2023 and held it in 6 quarters. The position peaked at $1.33M in Q4 2025. 270 funds tracked by Wall St. Rank hold ARQT as of Q1 2026.

  • Dark Forest Capital Management reported no remaining Arcutis Biotherapeutics position as of Q1 2026 after selling out during the quarter.
  • Dark Forest Capital Management sold 45,758 Arcutis Biotherapeutics shares in Q1 2026, an estimated $1.33M.
  • Dark Forest Capital Management first reported a position in Arcutis Biotherapeutics in Q3 2023 and held it in 6 quarters.
  • Dark Forest Capital Management's Arcutis Biotherapeutics position peaked at $1.33M in Q4 2025.
  • 270 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q1 2026.

Based on Dark Forest Capital Management's 13F filing for Q1 2026, filed 15 May 2026.